Bruce E. Johnson, MD, FASCO
ASCO PRESIDENT Bruce E. Johnson, MD, FASCO, commented on these study findings during the press briefing.
“This study adds to a growing body of knowledge showing the value of integrating patient-reported outcomes into routine oncology practice for symptom monitoring that a wide variety of our patients can participate in. We think this will increasingly become a way of getting timely information for both recognizing and treating symptoms, which will ultimately lead to reduced complications. This is particularly important in head and neck cancer, where people commonly have a lot of side effects….” ■
DISCLOSURE: Dr. Johnson has received research funding from Novartis and Toshiba and has patents and other intellectual property with royalties from Dana-Farber Cancer Institute.
A RANDOMIZED clinical trial evaluating the use of mobile and sensor technology to remotely monitor symptoms in patients receiving radiation therapy for head and neck cancer found that use of this technology reduced the severity of symptoms related to cancer and its treatment compared with usual...